AccessibilityHelp

Clinuvel Pharmaceuticals(NASDAQ) CUVL

Market Cap$253.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-22%
5 Year-82%
1 Year-33%
1 Month-13%
$5.00
-0.60%
-0.03Today
After hours$4.96-$0.04 (-0.80%)
Clinuvel Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 5.032026-10-22
Clinuvel Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.59%USD 5.062026-10-15
1 month-13.28%USD 5.802026-09-22
3 month-27.23%USD 6.912026-07-24
Year to date-40.36%USD 8.432025-12-30
1 year-33.01%USD 7.512025-10-22
3 year-50.36%USD 10.132023-10-23
5 year-82.49%USD 28.732021-10-22
Since inception-21.86%USD 6.442004-05-04

Clinuvel Pharmaceuticals Financials at a Glance

Market Cap

$253.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.46

P/E Ratio

10.85

Dividend

$0.04

Beta (Volatility)

0.64 (Low)

Price

$5.00

Volume

4,712

Open

$5.00

Previous Close

$4.94

Daily Range

$4.93 - $5.02

52-Week Range

$4.91 - $8.92

Estimated Earnings Date

Feb 23, 2027

CUVL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for genetic, metabolic, and life-threatening disorders. The company operates internationally, with a focus on providing solutions for patients suffering from conditions such as erythropoietic protoporphyria (EPP).

Products and Services
  • Lead drug candidate SCENESSE for phototoxicity prevention in EPP patients
  • Pipeline products include CUV9900 and PRÉNUMBRA for various disorders
  • Photocosmetic products aimed at DNA repair and skin protection
Growth Outlook
  • Strong market demand for innovative treatments in rare diseases
  • Expansion into new international markets enhances growth potential
  • Continued investment in research and development supports pipeline advancement
Financial Highlights
  • Market capitalization of approximately $304 million indicates solid investor interest
  • Recent stock price range between $5.57 and $8.92 reflects market confidence
  • Dividend yield of approximately 0.60% demonstrates commitment to shareholder returns
Clinuvel Pharmaceuticals Ltd. is positioned in the healthcare sector, focusing on innovative solutions for patients with specific medical needs. The company's lead product, SCENESSE, addresses a critical gap in treatment for EPP, showcasing its commitment to improving patient outcomes. With a robust pipeline and a strategic approach to market expansion, Clinuvel is well-placed to capitalize on the growing demand for specialized therapies. The financial highlights indicate a stable market presence, with a notable dividend yield that may attract investors seeking long-term growth potential.
AI Generated • Oct 4, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Philippe Jacques Wolgen, MD, MBA

Website

www.clinuvel.com

Headquarters

Melbourne, VIC 3000, AU

CUVL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

13.45%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

9.22%

Dividend Yield

0.71%

Payout Ratio

N/A

Stock Overview

Market Cap

$253.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.49M

Volume

4.71K

Avg. Volume

12.68K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Clinuvel Pharmaceuticals Performance Analysis

Clinuvel Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 52,687,10410.5%
20242024-06-30USD 57,789,8619.7%
20252025-06-30USD 61,536,3236.5%
20262026-06-30USD 63,713,0893.5%
Clinuvel Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 0.4035.8%
20242024-06-30USD 0.4615.2%
20252025-06-30USD 0.471.6%
20262026-06-30USD 0.45-2.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$253.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,635.64-0.00%
^DJIDJI
$52,319.47-0.01%
^IXICNASDAQ
$26,002.43-0.00%
BTCBitcoin
$81,534.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About CUVL

What is the current price of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals is trading at $4.94 per share.

What is the 52-week range for Clinuvel Pharmaceuticals?

Over the past 52 weeks, Clinuvel Pharmaceuticals has traded between $4.91 and $8.92.

How much debt does Clinuvel Pharmaceuticals have?

As of the most recent reporting period, Clinuvel Pharmaceuticals reported total debt of $1.34M.

How much cash does Clinuvel Pharmaceuticals have on hand?

Clinuvel Pharmaceuticals reported $14.16M in cash and cash equivalents in its most recent financial results.

What is Clinuvel Pharmaceuticals’s dividend yield?

Clinuvel Pharmaceuticals currently has a dividend yield of 0.71%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services